Abstract Background/Aims: Diabetes and Alzheimer's disease are often associated with each other, whereas the relationship between two diseases is ill-defined. Although hyperglycemia during diabetes is a major cause of encephalopathy, diabetes may also cause chronic inflammatory complications including peripheral neuropathy. Hence the role and the characteristics of inflammatory macrophages in the development of diabetic encephalopathy need to be clarified. Methods: Diabetes were induced in mice by i.p. injection of streptozotocin (STZ). Two weeks after STZ injection and confirmation of development of diabetes, inflammatory macrophages were eliminated by i.p. injection of 20µg saporinconjugated antibody against a macrophage surface marker CD11b (saporin-CD11b) twice per week, while a STZ-treated group received injection of rat IgG of same frequency as a control. The effects of macrophage depletion on brain degradation markers, brain malondialdehyde (MDA), catalase, superoxidase anion-positive cells and nitric oxide (NO) were measured. Results: Saporin-CD11b significantly reduced inflammatory macrophages in brain, without affecting mouse blood glucose, serum insulin, glucose responses and beta cell mass. However, reduced brain macrophages significantly inhibited the STZ-induced decreases in brain MDA, catalase and superoxidase anion-positive cells, and the STZ-induced decreases in brain NO. Conclusion: Inflammatory macrophages may promote development of diabetic encephalopathy.
Introduction
Diabetes and Alzheimer's disease are often associated with each other [1] [2] [3] [4] [5] [6] [7] [8] , whereas the relationship between two diseases is ill-defined. Many studies indicate that diabetic patients are at higher risk of developing dementia or Alzheimer's disease [1] [2] [3] [4] [5] . Indeed, diabetes can cause several complications, including diabetic encephalopathy, which is believed to result from hyperglycemic and inflammatory damages to brain vessels and causes dementia [9] [10] [11] [12] . The link between diabetes and Alzheimer's may occur as a result of the complex ways. For example, diabetes may increase the risk of developing mild cognitive impairment, a condition in which people experience more cognitive and memory problems than are usually present in normal aging [9] [10] [11] [12] . Mild cognitive impairment may lead to Alzheimer's disease and other types of dementia [9] [10] [11] [12] .
Although hyperglycemia during diabetes is one major cause of encephalopathy, diabetes may also cause chronic inflammatory complications including peripheral neuropathy [9] [10] [11] [12] . Since diabetes is one of the major risk factors for cerebrovascular disease, inflammatory process may take place in central nervous system (CNS). Diabetic encephalopathy is characterized by impaired cognitive functions and neurochemical and structural abnormalities, and may involve direct neuronal damage caused by hyperglycemia [9] [10] [11] [12] . However, brain inflammatory events during diabetes may be an important mechanism of brain damage and may be involved in diabetic encephalopathy. In this regard, brain innate immunity mediated primarily by activated and infiltrated macrophages, has been found to contribute to chronic central nervous system neurodegeneration [13] . However, the role and the characteristics of inflammatory macrophages in the development of diabetic encephalopathy remain to be clarified.
Here, we examined the role of inflammatory macrophages in the development of diabetic encephalopathy. Diabetes were induced in mice by i.p. injection of streptozotocin (STZ). Two weeks after STZ injection and confirmation of development of diabetes, inflammatory macrophages were eliminated by i.p. injection of 20µg saporin-conjugated antibody against a macrophage surface marker CD11b (saporin-CD11b) twice per week, while a STZ-treated group received injection of rat IgG of same frequency as a control. We found that saporin-CD11b significantly reduced inflammatory macrophages in the brain, without affecting mouse blood glucose, serum insulin, glucose responses and beta cell mass. However, reduced brain macrophages significantly inhibited the STZ-induced decreases in brain malondialdehyde (MDA), catalase and superoxidase anion-positive cells, and the STZinduced decreases in brain nitric oxide (NO).
Materials and Methods

Mouse handling
All mouse experiments were approved by the Institutional Animal Care and Use Committee at the Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University (Animal Welfare Assurance). Mice were housed in Pathogen-free environment. C57BL/6 mice were purchased from Jackson Labs (Bar Harbor, ME, USA). Sixty male mice were used in the current study. Blood glucose was measured after 3 hours' fasting every morning. Intraperitoneal glucose tolerance test (IPGTT) were performed as described before [14] . The beta-cell toxin streptozotocin (STZ) was i.p. injected at a dose of 150 mg/kg body weight to induce hyperglycemia in 40 mice. The other 20 mice were injected with saline and used as a control (untreated). Two weeks after STZ injection, the 40 mice were randomly divided into two groups (20 each). One group received i.v. injection of saporin-conjugated antibody (20µg; Advanced Targeting Systems, San Diego, CA, USA) against the macrophage surface marker CD11b twice per week to eliminate macrophages (STZ+saporin) [15] , while the other group received injection of rat IgG of same frequency as a control (STZ+IgG). Serum insulin levels were determined with an insulin ELISA kit (ALPCO, Salem, NH, USA).
Protein isolation and Western blot
Protein was extracted from mouse brain by RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) for Western Blot. The supernatants were collected after centrifugation at 12000×g at 4°C for 20min. Protein concentration was determined using BCA protein assay, and whole lysates were mixed with 4×SDS loading buffer (125 mmol/l Tris-HCl, 4% SDS, 20% glycerol, 100 mmol/l DTT, and 0.2% bromophenol blue) at a ratio of 1:3. Samples were heated at 100 °C for 5 min and were separated on SDS-polyacrylamide gels. The separated proteins were then transferred to a PVDF membrane. The membrane blots were first probed with a primary antibody. After incubation with horseradish peroxidase-conjugated second antibody, autoradiograms were prepared using the enhanced chemiluminescent system to visualize the protein antigen. The signals were recorded using X-ray film. 
Immunohistochemistry
Mouse pancreas and brain were dissected out and fixed with 4% paraformaldehyde for 10 hours, and then cyro-protected in 25% sucrose overnight. Samples were then sectioned in 6μM. Primary antibodies used in immunohistochemistry are guinea pig polyclonal anti-insulin (1:500; DAKO, Carpinteria, CA, USA) and rat polyclonal anti-F4/80 (1:200; Invitrogen). Secondary antibodies were HRP-conjugated antibodies for corresponding species (1:1000; Jackson ImmunoResearch Labs). After immunostaining, hematoxylin counterstaining was performed.
Quantification of beta-cell mass
Insulin staining was used to identify beta cells. The quantification of beta cell mass was done as has been described before [16] [17] [18] . Briefly, the pancreas was weighed and then fixed with 4% Paraformaldehyde for 10 hours, and then cyro-protected in 25% sucrose overnight in a way to allow longitudinal sections from tail to head of the pancreas to be obtained. Sections at 120µm intervals from whole pancreas were immunostained for insulin and analysed using NIH Image J software. The relative cross-sectional area of beta cells was determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue. The beta-cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells per total tissue and the weight of the pancreas. The beta-cell mass was calculated by examining pancreas from all 20 animals in each group. 
Measurement of nitrite/nitrate production
Measurement of thiobarbituric reactive substances (TBARS)
Brain malondialdehyde (MDA) content was assessed by the thiobarbituric acid assay. Perfused brain sections were homogenized in a buffer containing 100mmol/l KCl and 3mmol/l EDTA. Afterwards, the homogenates were centrifuged at 600g for 15 min. A volume of supernatant was added to a solution containing 8.1% SDS, 20% acetic acid and 0.8% thiobarbituric acid, at pH=3.5 (Sigma-Aldrich). The complete mixture was heated to 95 °C for 60 min; afterwards, the chromogenic substrate was extracted into the organic phase with butanol/pyridine (15:1). Absorbance of the organic layer was measured at 532nm. As external standard the MDA bisdimethyl acetal (Sigma-Aldrich) was used and results were expressed as nmol per mg of protein.
Measurement of catalase activity
To determine catalase activity, perfused brain slides from control and diabetic mice were homogenized in 50mmol potassium phosphate buffer at pH=7.2. The homogenates were centrifuged at 600g for 10 min and enzymatic activity was measured in the supernatant. Catalase activity was determined by spectrophotometrical assay by the conversion rate of 7.7mmol/l H 2 O 2 in 50mmol/l potassium phosphate at pH=7.0 (Sigma-Aldrich). The change in absorbance was read at 250nm and the rate constant of a first order reaction (k) was used. Results are expressed as k per mg of homogenate proteins.
Histological identification of superoxide anion
Superoxide anion production was determined at cellular levels in the different brain zones by a cytochemical method previously described (Briggs et al., 1986). Briefly, brain frozen sections (10μm) from controls and diabetic rats were incubated in a solution containing 0.05mol/l Tris-HCl buffer, 0.05mol/l DAB, 8% NiCl, 10% NaN 3 and 0.5mol/l MnCl 2 at pH=7.6 for 60min at 37°C (Sigma-Aldrich). Afterwards, sections were fixed with 10% formalin and counterstained with 1% methyl green. Results were expressed as positive cells per mm 2 .
Statistics
All values are depicted as mean ± standard error and are considered significant if p < 0.05. All data were statistically analysed using one-way ANOVA with a Bonferoni correction, followed by Fisher's Exact Test, using GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA).
Results
Experimental model
In order to find out whether inflammatory macrophages may play a critical role in the development of diabetic encephalopathy, we used 60 12 week-old C57BL/6 male mice in this study. The beta-cell toxin streptozotocin (STZ) was i.p. injected at a dose of 150 mg/ kg body weight to induce hyperglycemia in 40 mice. The other 20 mice were injected with saline and used as a control (untreated). Two weeks after STZ injection, the 40 STZ-treated mice were randomly divided into two groups (20 each). One group received i.v. injection of saporin-conjugated antibody against the macrophage surface marker CD11b twice per week to eliminate macrophages (STZ+saporin), while the other group received injection of rat IgG of same frequency as a control (STZ+IgG). Another 4 weeks later, the mice were sacrificed for analyses. Blood glucose was measured after 3 hours' fasting every morning every week. Serum insulin levels were determined biweekly. At 6 weeks (the end of experiment), IPGTT were performed. Beta cell mass, macrophages in brain, and the effects of macrophage depletion on brain degradation markers, brain malondialdehyde (MDA), catalase, superoxidase anionpositive cells and nitric oxide (NO) were measured (Fig. 1A) . 
Saporin-CD11b significantly reduces inflammatory macrophages in the brain
Then we analyzed whether Saporin- CD11b altered brain inflammatory macrophages in the STZ-treated mice. We found that saporin treatments significantly reduced the F4/80 (a pan-macrophage marker) transcripts (Fig. 3A) and protein (Fig. 3B) in the brain from STZ-treated mice, which was also supported by immunohistochemistry for F4/80 in these mice, shown by quantification (Fig. 3C ) and by representative images (Fig. 3D) . Together, these data suggest that Saporin-CD11b significantly reduces inflammatory macrophages in the brain.
Macrophage depletion rescues brain degradation events in STZ-treated mice
Then the effects of macrophage depletion on brain degradation markers, brain malondialdehyde (MDA), catalase, superoxidase anion-positive cells and nitric oxide (NO) were measured. We found that saporin-CD11b significantly inhibited the STZ-induced decreases in brain MDA (Fig. 4A) , catalase (Fig. 4B ) and superoxidase anion-positive cells (Fig. 4C) , and the STZ-induced decreases in brain NO (Fig. 4D) . These data suggest that macrophage depletion rescues brain degradation events in STZ-treated mice (Fig. 5) .
Discussion
Diabetes is a chronic and prevalent disease that is supposed to predispose development of Alzheimer's disease [1] [2] [3] [4] [5] [6] [7] [8] . Indeed, previous studies have demonstrated that diabetic encephalopathy is one of the main complications of severe diabetes, and is believed to result from hyperglycemic and inflammatory damages to brain vessels and causes dementia [9] [10] [11] [12] . Moreover, diabetes may increase the risk of developing mild cognitive impairment, a condition in which people experience more cognitive and memory problems than are usually present in normal aging [9] [10] [11] [12] . Mild cognitive impairment may lead to Alzheimer's disease and other types of dementia [9] [10] [11] [12] . Although great efforts have been made, the previous knowledge on the molecular mechanisms is far from completeness.
Hyperglycemia is the major inducer of encephalopathy, whereas chronic inflammation substantializes the process by impairing normal brain vessel function [9] [10] [11] [12] . Thus, brain inflammatory events during diabetes may be an important mechanism of brain damage and may be involved in diabetic encephalopathy. Activated and infiltrated macrophages have been found to contribute to chronic central nervous system neurodegeneration [13] . However, the exact role and the characteristics of these inflammatory macrophages remain unclear.
Here, we used a mouse STZ-diabetes model to examine the role of inflammatory macrophages in the development of diabetic encephalopathy. Diabetes were induced in mice by i.p. injection of STZ. STZ selectively kills pancreatic beta cells in a very short time and beta cells do not regenerate naturally [19] , which was confirmed in our study. Two weeks after STZ injection and confirmation of development of diabetes by blood glucose, serum insulin and immunohistochemistry for insulin, which is a beta-cell-specific marker, we eliminated inflammatory macrophages by i.p. injection of 20µg saporin-conjugated antibody against a macrophage surface marker CD11b (saporin-CD11b) twice per week, while a STZ-treated group received injection of rat IgG of same frequency as a control. CD11b is a specific marker for macrophages. We used a saporin-conjugated antibody against CD11b to eliminate macrophages. Saporin is a ribosome-inactivating protein from seeds of the plant Saponaria officinalis. Saporin is safe for laboratory use under normal safety conditions and the LD50 in mice is 4 mg/kg. Moreover, saporin does not have a method of cell entry on its own. Thus, CD11b antibody will direct entrance of Saporin into macrophages to selectively kill them. We found that saporin-CD11b significantly reduced inflammatory macrophages in the brain, without affecting mouse blood glucose, serum insulin, glucose responses and beta cell mass. These data assure that the effects of macrophage depletion on brain are not secondary to changes of systemic glucose metabolism.
However, reduced brain macrophages significantly inhibited the STZ-induced decreases in brain malondialdehyde (MDA), catalase and superoxidase anion-positive cells, and the STZ-induced decreases in brain nitric oxide (NO). All these parameters are related to brain degradation. Thus, macrophage depletion protects the brain from degradation-associated events, or in another word, inflammatory macrophages may play a substantial role in the process of diabetic encephalopathy. Future experiments may be applied to further elucidate the underlying molecular mechanisms.
Together, our study demonstrate that inflammatory macrophages promotes development of diabetic encephalopathy, highlighting inflammatory macrophages may be a promising therapeutic target for treating diabetic encephalopathy to prevent the development of dementia.
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